311 results about "Kidney cell" patented technology

Human/human hybrid cells were made via fusion of human embryonic kidney cells (293S) and modified Burkitt's lymphoma cells (2B8). The fusion cells are useful as host cells for the recombinant expression of mammalian genes. The advantages of using these hybrid clones of human kidney- and B-cells, called HKBs, for mammalian gene expression, include (i) the cells are negative for immunoglobulin expression, (ii) the cells grow easily in plasma protein-free medium (with or without the addition of recombinant insulin) as suspension cultures in a shake flask or in a fermenter (iii) the cells are very susceptible for transfection of DNA, and (iv) the cells secrete high levels of heterologous recombinant proteins, such as recombinant monoclonal antibodies, soluble ICAM-1, rIL-4, and rFVIII.

A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell line can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, measles virus.

The present invention provides an sgRNA sequence for knocking out the human CYP2E1 gene. The target DNA sequence of the sgRNA is at least one of the sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2. The present invention also provides a method for knocking out CYP2E1 gene of human embryonic kidney cells, which is adapted to transform CYP2E1 gene in human embryonic kidney cells by using CRISPR/Cas system. The invention also provides a CYP2E1 knockout cell strain. CYP2E1 involves in the important metabolism function of a human body. The CYP2E1 gene knock-out cell strain provided by the invention provides an effective platform for studying the metabolism function of exogenous chemical or exogenous poison in the body, and a powerful tool for studying chronic diseases (such as alcoholic liver disease and diabetes) and tumor-related diseases.

The invention relates to a porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine and a preparation method of the porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine. The porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine is prepared by performing virus amplification on a swine testicular cell line (ST cells) or an African green monkey kidney cell line (Vero cells) by using a self-attenuated and preserved transmissible gastroenteritis virus SD/L strain and a self-attenuated and preserved porcine epidemic diarrhea virus LW/L strain, and carrying out the steps of harvesting, uniformly mixing, freeze-drying and the like. The porcine transmissible gastroenteritis and epidemic diarrhea combined live vaccine can effectively prevent two diseases namely swine transmissible gastroenteritis and epidemic diarrhea.

The invention relates to polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, a preparation method thereof and application thereof. The preparation method comprises the step of directly condensing carboxyl in the polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine segmented copolymer with amino in polyethyleneimine to form the graft copolymer. The copolymer is a polycation gene carrier, integrates the advantages of polyethylene glycol, Makrolan and polyethyleneimine, and has high transfection efficiency, wherein the highest transfection efficiency to the medium luciferase plasmid of african green monkey kidney cell is 14 times of that of American Invitrogen biological company transfection reagent Lipofetamine<TM>2000, can effectively antagonize the inhibiting effect of blood serum to the transfection, and has less cell toxicity, wherein consistency thereof is not higher than 200 microgramme/ml and cell survival rate is more than 80%.

The invention discloses a method for constructing a kidney cell line of scophthalmus maximus, which comprises the following steps of: preparing a cell culture fluid first, taking a kidney tissue of the scophthalmus maximus as a material, using 0.5 percent trypsinase to digest the kidney tissue for 30 minutes at room temperature after the rinsing and shearing, adopting an 200-mesh nylon gauze to filter and collect cells, split charging the cells with the quantity of 5-10*10 counts/bottle into culture bottles with the growth area of 25 cm, and placing the culture bottles at a temperature of 24 DEG C for culturing; replacing the cell culture fluid with half quantity each four days, and using 0.25 percent trypsinase digest the cells for passage when primary cells grow to be monolayered; and performing passage once each 8 to 10 days, wherein the content of serum in the cell culture fluid is reduced to 10 percent from 20 percent when the 8th generation is reached, and the cell line is successfully established at the moment. The kidney cell line of the scophthalmus maximus obtained by utilizing the method is fibroid and can be continuously transferred for more than 40 generations; the cell line can be directly applied to pathogeny characteristics research, vaccine development and functional gene research; and the construction method is suitable to construct kidney cell lines of other fishes.

The invention relates to a beta-cyclodextrin-modified polyamide-dendrimer and a preparation method of a gold nanoparticle compound of the beta-cyclodextrin-modified polyamide-dendrimer. The preparation method includes: mixing DMSO (dimethyl sulfoxide) solutions in which beta-CD and CD I are dissolved, respectively, adding DMSO solution of G5PAMAM after reacting, performing stirring at room temperature for 3 d, and performing dialysis and freeze-drying to obtain G5.NH2-beta-CD; adding HauCl4.4H2O solution into the obtained G5.NH2-beta-CD solution, adding NaBH4 solution after stirring, performing stirring for 2-4 h, and performing dialysis and freeze-drying to obtain a target compound {(Au0)25-G5.NH2-beta-CD}. The prepared compound is a good gene carrier, capable of successfully carrying and expressing pDNA-transfected human embryonic kidney cells, transfection conditions are mild, operating is easy, transfection efficiency is high, and the compound has a promising application in terms of biomedicine such as gene therapy.

The invention discloses a serum-free medium suitable for large-scale single-cell suspension culture of young hamster kidney cells (BHK cells), including 21 kinds of amino acids, 11 kinds of inorganic salts, 12 kinds of vitamins, 1 kind of protein hydrolyzate, 2 kinds of Lipids, 2 buffer components and 6 additives. The BHK cell serum-free medium of the present invention produces biological products by single-cell suspension culture, which can not only avoid various disadvantages of serum culture, but also eliminate the problem of difficult scale-up of roller bottle adherent culture, thereby improving the production efficiency of BHK cell culture And reduce production costs, while ensuring product quality, has good application value and huge market prospects.

The present invention relates to viral particles as immunogens against enterovirus infection and a method of producing the same. Specifically, the present invention features that human embryo kidney 293 (HEK 293) cells are used to produce viral particles of Enterovirus A, particularly Coxsackievirus A6 (CVA6) particles or Coxsackievirus A10 (CVA10) particles or both and optionally additional viral particles of other Enterovirus A e.g. Coxsackievirus A16 (CVA16) and/or Enterovirus A71 (EV71). The yield of the viral particles in HEK 293 cells is unexpectedly high and effective to induce an immune response against enterovirus infection, especially CVA6 and CVA10. The present invention also relates to an immunogenic composition against enterovirus infection for human use comprising the viral particles as described herein and a method of preventing enterovirus infection or a disease as caused, particularly Hand-Foot-Mouth diseases (HFMD), by administering the immunogenic composition to a subject in need thereof.

Described herein are organoids comprising admixtures of selected bioactive primary renal cells and a bioactive cell population, e.g., an endothelial cell populations, e.g. HUVEC cells, and methods of treating a subject in need thereof with such organoids. Further, the isolated renal cells, which may include tubular and erythropoietin {EPO}-producing kidney cell populations, and/or the endothelial cell populations may be of autologous, syngeneic, allogeneic or xenogeneic origin, or any combination thereof. Further provided are methods of treating a subject in need with the organoids.

The invention discloses a culture medium and an organoid culture method for 3D culture of kidney tissue organoids. According to culture and growth characteristics of kidney-tissue-derived cells, the culture medium disclosed by the invention is prepared by blending a plurality of selected cytokine components in certain proportion; so that, signaling pathway regulatory factor content of the cytokines in the blended culture medium is appropriate. Thus, effective formation of organoids by kidney cells and renal cancer cells in 3D environment is allowed.

Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro, and methods of use thereof. The cells may be provided in a three dimensional matrix for culturing in vitro and/or implanting in vivo. Methods of seeding cells onto the matrix are also provided.

The invention provides a coxsackie virus A16-type virus strain. The collection number of the coxsackie virus A16-type virus strain is CGMCC No.5372, wherein CGMCC refers to China General Microbiological Culture Collection Center. The virus is a 20-face stereoscopic symmetrical sphere under observation through an electron microscope, and the diameter of the virus is 23-30nm. VP1 conserved region sequence analysis and mass spectrum analysis are respectively performed on the virus strain, and a result shows a CA16 virus. The CA16 virus can be efficiently proliferated in Vero cells (African green monkey kidney cells), and the virus titer can reach 6.61g CCID50/ml. Moreover, the virus strain has no external pollution, better immunogenicity and a good effect.

The invention discloses a method for preparing a double yolk antibody of a porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. The method comprises the following steps of: performing porcine transmissible gastroenteritis virus multiplication on porcine kidney cells (PK15); performing porcine epidemic diarrhea virus multiplication on African green monkey kidney cells (Vero); emulsifying the two cell cultures used as antigen with an oil emulsion adjuvant to prepare immunogen, namely, mixing the two kinds of viruses in a ratio of (1-3):(1-3) to prepare the immunogen; immunizing non-immunologic laying hens; and obtaining the double yolk antibody which can prevent and treat porcine transmissible gastroenteritis and porcine epidemic diarrhea based on the collection and purification of the yolk. When the double yolk antibody is used for curing experimental pigs, the clinical symptoms in the experiment are obviously reduced compared with a control group, and the death rate of the experimental group is obviously lower than that of the control group. The double yolk antibody has obvious preventing and treating functions when applied in a pig farm with high incidence rate of the porcine transmissible gastroenteritis and the porcine epidemic diarrhea.

Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.

The invention provides a cell culture method for duck flavivirus. The method comprises the following steps: inoculating to attach an anchorage-dependent kidney cell BHK21 of a baby hamster to the surface of a cell culture container to form a monolayer; inoculating the monolayer with virus; culturing the monolayer inoculated with the virus in an incubator with 5% CO2 at 37 DEG C; and continuously passing by taking a cell culture product as an inoculum for the next passage. According to the cell culture method provided by the invention, after the virus is continuously passed for 5-7 generations on the monolayer, stable multiplication can be obtained; and after the cell is inoculated for 3-4 days, an obvious cytopathic effect can be formed. The method provides a convenient and visual virus operating platform for studying the biological characteristics of the virus and the molecular basis of virus pathopoiesia and for the vaccine research developed for effectively preventing and controlling the disease.

A duck hemorrhagic oophoritis inactivated vaccine production method by using a cell line and a product thereof belong to the field of biotechnology. According to the method provided by the invention, the cell line is selected from hamster kidney cell line or African green monkey kidney cell line, and the preparation of the vaccine is accomplished by the following steps of: (1) breeding strain, (2) establishing virus seed group, (3) preparing cell venom, (4) inactivating virus, (5) washing and concentrating cell venom, (6) emulsifying and the like. The method provided by the invention has characteristics of simple and stable production process, easy operation and high security. The prepared duck hemorrhagic oophoritis inactivated vaccine has advantages of high quality, high yield, low cost, small inter-batch difference, good safety and high immune efficacy.

A device for culturing, storing and expanding adherent renal cells. The device permits the adhesion and proliferation of the cells and the surface characteristics of the membrane material used in said device further permit the cellular matrix components (EMC). A method for expanding adherent renal cells and methods of using particular membranes for culturing, storing and expanding adherent renal cells. The membranes comprise a copolymer of acrylonitrile and sodium methallyl sulfonate as well as polyethylenimine.

This application invention discloses bioartificial proximal tubule device, constructed by preparing a decellularized biological matrix, seeding the biological matrix with mammalian kidney-derived cells and optionally mammalian endothelial cells. The device may then be cultured statically or matured using bioreactor culture to allow differentiation of the kidney cells into functioning proximal tubule cells. The device is capable of carrying out proximal tubule functions. The application also describes various methods of making the proximal tubule devices. The application also further describes methods of use of bioartificial proximal tubule devices for e.g. in vitro studies of tubule cell transport, toxicity effects of various compounds or pharmaceutical compound screening.

The invention discloses a polypeptide molecule exerting selective killing and migration inhibiting effect on cancer cells, and a design method and application thereof, belonging to the technical field of application of biopharmacy. The polypeptide molecule comprises a polypeptide amino acid sequence and constituent (SEQ ID No. 1) and contains altogether 12 amino acids. Through 9R or 8R coupling reconstruction and designing, the polypeptide molecule has strong killing effect on malignant cells of human liver cancer, prostatic cancer, breast cancer and the like and low killing effect on normal human hepatic cells, embryonic kidney cells and umbilical vein endothelial cells; in particular, the polypeptide molecule has strong selective killing effect on liver cancer cells and inhibitory effect on migration of human liver cancer and umbilical vein endothelial cells compared with normal human hepatic cells. The polypeptide molecule is mainly applied to preparation of drugs used for selective killing and migration inhibiting of malignant cells of human liver cancer.

The invention discloses a polypeptide hydrogel. The polypeptide hydrogel is prepared by mixing a self-assembled peptide (SAP) aqueous solution with exosomes (Exos). The present invention also discloses a preparation method and application of the polypeptide hydrogel. The polypeptide hydrogel provided by the invention can effectively slow down the release of the Exos and prolong the half-life of the Exos; and the released Exos have the activity similar to that of newly-separated Exos, and can effectively reduce HK2 cell injury caused by hypoxia and promote the recovery of vascular endothelial damage. The polypeptide hydrogel disclosed by the invention is capable of effectively reducing acute kidney injury and slowing down renal fibrosis by reducing kidney cell apoptosis and inflammatory factors, the expression amount of kidney injury marker protein-neutrophil gelatinase-related apolipoprotein (NGAL), and the synthesis and secretion of renal extracellular matrix (ECM), and has a good clinical application prospect.

The preparation process of reovirus antigen subunit vaccine for grass carp includes the following steps: proliferation of GCRV873, which is the Hunan Shaoyang strain of reovirus, in grass carp kidney cell line; centrifugal purification and concentration of GCRV873 infected cell virus suspension; processing purified virus with surfactant to disintegrate complete virus structure to form viral nucleic acid and capsid protein subunit component; digesting with nuclease to degrade free virus genome dsRNA; dialysis to obtain reovirus protein subunit antigen preparation for grass carp containing no nuclease; and diluting with physiological saline to obtain the said vaccine. The vaccine of the present invention has the advantages of containing complete virus protein antigen component, containing no genetic virus matter RNA, simple preparation process, high product purity, etc.